KRONOS BIO INC (KRON)

Company Profile

Kronos Bio, Inc. is a clinical development biopharmaceutical company. The company is headquartered in San Mateo, California and currently employs 99 full-time employees. The company went IPO on 2020-10-09. The firm is focused on developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. The company focuses on advancing two investigational compounds in clinical trials for patients with cancer. The Company’s product engine includes its proprietary small molecule microarray (SMM) screening platform, which provides the capability to map and target transcription regulatory networks (TRNs) in a differentiated manner to enable discovery of novel compounds and improve its ability to discover and optimize clinical development candidates. Its pipeline includes KB-0742 and Lanraplenib. KB-0742 is an oral cyclin dependent kinase 9 (CDK9) inhibitor for the treatment of MYC-amplified and other transcriptionally addicted solid tumors. Lanraplenib is a small molecule selective inhibitor targeting spleen tyrosine kinase (SYK), a critical node in a dysregulated TRN within acute myeloid leukemia (AML).

Company Info

KRONOS BIO INC

1300 S. El Camino Real, Suite 400

San Mateo CALIFORNIA 94402

P: 16507815200

CEO: Norbert Bischofberger

Employees: 99

Website: https://kronosbio.com/